Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash from Investing Activities: 2023-2025

Historic Cash from Investing Activities for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to -$95.2 million.

  • Compass Therapeutics' Cash from Investing Activities fell 427.92% to -$95.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$74.6 million, marking a year-over-year decrease of 297.68%. This contributed to the annual value of $46.8 million for FY2024, which is 73.45% up from last year.
  • Per Compass Therapeutics' latest filing, its Cash from Investing Activities stood at -$95.2 million for Q3 2025, which was down 1,396.16% from -$6.4 million recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Cash from Investing Activities ranged from a high of $29.0 million in Q3 2024 and a low of -$95.2 million during Q3 2025.
  • Moreover, its 3-year median value for Cash from Investing Activities was $6.3 million (2023), whereas its average is -$1.5 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first skyrocketed by 1,071.96% in 2024, then slumped by 427.92% in 2025.
  • Quarterly analysis of 3 years shows Compass Therapeutics' Cash from Investing Activities stood at $6.3 million in 2023, then soared by 143.43% to $15.4 million in 2024, then tumbled by 427.92% to -$95.2 million in 2025.
  • Its last three reported values are -$95.2 million in Q3 2025, -$6.4 million for Q2 2025, and $11.6 million during Q1 2025.